ANNAPOLIS – Biodefense company PharmAthene has received up to $78.4 million in additional funding from the U.S. Department of Health and Human Services, provided that certain milestones are achieved.  The award will support the continued advanced development of SparVax, a second generation recombinant protective antigen anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.  You can thank me later for stripping out the inscrutable acronyms in this one.

See full release.